VETOQUINOL SA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 98.3 EUR | -1.11% |
|
-3.25% | -4.00% |
| Apr. 30 | Vetoquinol: down after sales update | CF |
| Apr. 29 | Vetoquinol SA Reports Sales Results for the First Quarter of Fiscal 2024 | CI |
| Sales 2024 * | 551M 599M | Sales 2025 * | 577M 628M | Capitalization | 1.18B 1.28B |
|---|---|---|---|---|---|
| Net income 2024 * | 56M 60.89M | Net income 2025 * | 61M 66.32M | EV / Sales 2024 * | 1.8 x |
| Net cash position 2024 * | 183M 199M | Net cash position 2025 * | 235M 255M | EV / Sales 2025 * | 1.63 x |
| P/E ratio 2024 * |
20.8
x | P/E ratio 2025 * |
19.2
x | Employees | 2,440 |
| Yield 2024 * |
0.78% | Yield 2025 * |
0.84% | Free-Float | 32.57% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -0.80% | ||
| 1 week | -2.95% | ||
| Current month | -3.33% | ||
| 1 month | +4.67% | ||
| 3 months | -3.90% | ||
| 6 months | +8.35% | ||
| Current year | -3.71% |
1 week
98.60
105.00
1 month
93.80106.00
Current year
92.60110.00
1 year
76.30110.00
3 years
76.30161.00
5 years
41.90161.00
10 years
32.10161.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 01-04-01 | |
| Director of Finance/CFO | 59 | - | |
Philippe Gruet
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Étienne Frechin
BRD | Director/Board Member | 86 | 62-07-01 |
| Chief Executive Officer | 55 | 01-04-01 | |
Philippe Arnold
BRD | Director/Board Member | 83 | 07-06-03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +4.32% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 98.3 | -1.11% | 483 |
| 24-06-05 | 99.4 | -1.19% | 1,307 |
| 24-06-04 | 100.6 | -2.71% | 3,389 |
| 24-06-03 | 103.4 | +1.37% | 2,017 |
| 24-05-31 | 102 | +0.39% | 1,335 |
Real-time Euronext Paris, June 06, 2024 at 04:10 am EDT
More quotes
Vetoquinol SA specializes in the research, development, production and marketing of veterinary drugs and products for pets (67.7% of net sales; dogs, cats, etc.) and livestock (32.3%; cattle, pigs, poultry, etc.). The group's activity is organized around 4 product families:
- antibiotics;
- anti-inflammatories;
- cardiology and nephrology treatments;
- other: anti-parasitics, vaccines, and nutritional products.
At the end of 2022, the group had 5 production sites throughout the world.
Net sales are distributed geographically as follows: Europe (46.7%), the Americas (36%) and Asia/Pacific (17.3%).
Sector
Pharmaceuticals
Calendar
2024-09-11
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
99.4
EUR
Average target price
105.8
EUR
Spread / Average Target
+6.47%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.71% | 1.28B | |
| -10.92% | 80.23B | |
| +23.83% | 9.12B | |
| +24.38% | 3.68B | |
| +0.56% | 3.27B | |
| +12.67% | 1.67B | |
| -26.65% | 1.22B | |
| -28.50% | 1.19B | |
| -19.43% | 1.05B | |
| -9.88% | 943M |
- Stock Market
- Equities
- VETO Stock
